<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical Trial | CSE Tracker</title>
    <link>https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/</link>
      <atom:link href="https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/index.xml" rel="self" type="application/rss+xml" />
    <description>Clinical Trial</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 25 Mar 2021 09:00:00 -0800</lastBuildDate>
    <image>
      <url>https://master--youthful-lamport-190a0e.netlify.app/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>Clinical Trial</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/category/20210325clinical-trial/</link>
    </image>
    
    <item>
      <title>Designing a Randomized Trial with Sample Size Re-estimation - Challenges and Best Practices</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</link>
      <pubDate>Thu, 25 Mar 2021 09:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</guid>
      <description>&lt;p&gt;In this webinar, we will play the part of a sponsor consulting a statistician with the goal of designing a randomized trial with sample-size re-estimation. We will discuss the concept of conditional power and the promising-zone method, and we will present a pragmatic view of some issues, including when to plan the sample-size re-estimation in the course of the accrual, how to select the amount of sample-size increase, and how to operate such trials in practice. We will also discuss the pros- and cons- of using this type of design in relation to the clinical setting in which the trial is designed and endpoints it uses. Moreover, we will discuss the regulators’ views and illustrate our discussion with practical examples.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PSI Journal Club: Survival Analysis</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210324psi-journal-club-survival-analysis/</link>
      <pubDate>Wed, 24 Mar 2021 09:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210324psi-journal-club-survival-analysis/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Non‐proportional hazards in immuno‐oncology: Is an old perspective needed?&lt;/strong&gt;&lt;br&gt;
&lt;em&gt;Publication: Dominic Magirr, Pharmaceutical Statistics. 2020;1-16&lt;/em&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect&lt;/strong&gt;&lt;br&gt;
&lt;em&gt;Publication: Chang Yu, Xiang Huang, Hui Nian and Philip He, Pharmaceutical Statistics. 2021;1-23&lt;/em&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>The Importance of Representative Samples in Clinical Trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323the-importance-of-representative-samples-in-clinical-trials/</link>
      <pubDate>Tue, 23 Mar 2021 10:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323the-importance-of-representative-samples-in-clinical-trials/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://ds.dfci.harvard.edu/event/data-science-zoominar-the-importance-of-representative-samples-in-clinical-trials/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Event Page&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Cardiac Safety from Preclinical to the Clinic – Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323cardiac-safety-from-preclinical-to-the-clinic-industry-and-regulatory-trends-in-t-qt-and-concentration-qt-studies-for-assessing-qt-prolongation-risks/</link>
      <pubDate>Tue, 23 Mar 2021 08:30:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323cardiac-safety-from-preclinical-to-the-clinic-industry-and-regulatory-trends-in-t-qt-and-concentration-qt-studies-for-assessing-qt-prolongation-risks/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Symposium Agenda (All times are in Pacific Time)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Day 1: March 23, 2021&lt;/strong&gt;&lt;br&gt;
&lt;span style=&#34;color:grey&#34;&gt;
&lt;em&gt;8:30-8:45am:&lt;/em&gt; Introductions&lt;br&gt;
&lt;em&gt;8:45-9:30am:&lt;/em&gt; State-of-the-Art: TQT studies (QT and C-QT Analyses, Challenges &amp;amp; Examples) - Borje Darpo (ERT)&lt;br&gt;
&lt;em&gt;9:30-10:15am:&lt;/em&gt; Cardiac safety and TQT waivers (Types of studies - FIH, Food effect, DDI and timing, Issues with ECG collection) - Jay Mason (Spaulding)&lt;br&gt;
&lt;em&gt;10:15-10:25am:&lt;/em&gt; Sponsor Presentation&lt;br&gt;
&lt;em&gt;10:25-10:40am:&lt;/em&gt; Break&lt;br&gt;
&lt;em&gt;10:40-11:25am:&lt;/em&gt; TBD&lt;br&gt;
&lt;em&gt;11:25am-12:10pm:&lt;/em&gt; New opportunities for C-QT and C-QT in non-ideal scenarios - Lauren Lohmer (Nuventra)&lt;br&gt;
&lt;em&gt;12:10pm-12:40pm:&lt;/em&gt; Panel Discussion&lt;br&gt;
&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Day 2: March 24, 2021&lt;/strong&gt;&lt;br&gt;
&lt;span style=&#34;color:grey&#34;&gt;
&lt;em&gt;8:30-8:45am:&lt;/em&gt; Introductions&lt;br&gt;
&lt;em&gt;8:45-9:30am:&lt;/em&gt; Case Study - Biologics C-QT project supporting a major readout - Yehong Wang (Genentech)&lt;br&gt;
&lt;em&gt;9:30-10:15am:&lt;/em&gt; TBD&lt;br&gt;
&lt;em&gt;10:15-10:25am:&lt;/em&gt; Sponsor Presentation&lt;br&gt;
&lt;em&gt;10:25-10:40am:&lt;/em&gt; Break&lt;br&gt;
&lt;em&gt;10:40-11:25am:&lt;/em&gt; Non-clinical aspects related to the ICH Q&amp;amp;A - Anne Bonneville (Terns Pharmaceuticals)&lt;br&gt;
&lt;em&gt;11:25pm-12:05pm:&lt;/em&gt; Panel Discussion 
&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Non-Randomized Studies and Utilization of Real-World Evidence</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201217non-randomized-studies-and-utilization-of-real-world-evidence/</link>
      <pubDate>Thu, 17 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201217non-randomized-studies-and-utilization-of-real-world-evidence/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Data Monitoring and Adaptive Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Innovations in Bayesian Trials Virtual Symposium</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201108innovations-in-bayesian-trials-virtual-symposium/</link>
      <pubDate>Sun, 08 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201108innovations-in-bayesian-trials-virtual-symposium/</guid>
      <description>&lt;p&gt;This dynamic program will cover a range of topics presented by Bayesian experts in academia, regulatory and industry. The presentations will include: Adaptive design, platform studies, complex innovative designs using Bayesian modeling; Regulatory acceptability of Bayesian designs; Leveraging external information using Bayesian priors.&lt;br&gt;
&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, October 8, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Statistics and FDA Regulatory Acceptability&lt;/strong&gt;&lt;br&gt;
Greg Campbell, PhD, President, GCStat Consulting (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691488&amp;amp;sessionid=1&amp;amp;key=7C84CEA899224E2CDE4F7E22CFABDECB&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, October 22, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Dose-finding Designs for Modern Drug Development&lt;/strong&gt;&lt;br&gt;
Yuan Ji, Professor of Biostatistics, Department of Public Health Sciences, The University of Chicago (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691496&amp;amp;sessionid=1&amp;amp;key=08500FE422DAFE88617C8485AB42E961&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, Novermber 05, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Dynamic Borrowing for Partial Extrapolation and Bridging Studies: Methods and Case Studies&lt;/strong&gt;&lt;br&gt;
Nicky Best, Head, Advanced Biostatistics and Data Analytics Centre of Excellence, GSK (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691499&amp;amp;sessionid=1&amp;amp;key=3C8FF73C92BC880B2A5989FDE9074FF5&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, November 19, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Statistical Design and Conduct of Platform Trials&lt;/strong&gt;&lt;br&gt;
Jason Connor, President &amp;amp; Lead Statistical Scientist, ConfluenceStat (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691515&amp;amp;sessionid=1&amp;amp;key=4B07CFCA81196A4A8DDB075F8E813266&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, December 3, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Models for Precision Oncology Clinical Trials&lt;/strong&gt;&lt;br&gt;
Peter Mueller, Professor, Department of Mathematics and the
Department of Statistics &amp;amp; Data Science, The University of Texas at Austin (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691509&amp;amp;sessionid=1&amp;amp;key=7B1DA30C7762FC9B3DB4A0EABBE36DD9&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, December 10, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Recent Development on Bayesian Clinical Trial Designs Using Historical Data&lt;/strong&gt;&lt;br&gt;
Ming-Hui Chen, Professor and Head of the Department of Statistics, The University of Connecticut (1hr) 
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691518&amp;amp;sessionid=1&amp;amp;key=B3CA28FA4552CAB13C45A32C412748AD&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday March 11, 2021&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Leveraging external evidence in medical device decision-making&lt;/strong&gt;&lt;br&gt;
Ram C. Tiwari, Ph.D. Head of Statistical Methodology, Bristol Myers Squibb&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=3024363&amp;amp;sessionid=1&amp;amp;key=BD2CA3B8AB7D9856260F5287B7FE45B3&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>2020 New England Rare Disease Statistics (NERDS) Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/202011022020-new-england-rare-disease-statistics-nerds-webinar-series/</link>
      <pubDate>Mon, 02 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/202011022020-new-england-rare-disease-statistics-nerds-webinar-series/</guid>
      <description>&lt;p&gt;&lt;strong&gt;1. Introductory NERDS Session&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;How to Select Endpoints and Quantify Treatment Effect in a Comparative Clinical Study on COVID-19 Diseases (L.J. Wei (Harvard))&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Borrowing Information from Historical Data: A Double-edged Sword (Ying Yuan (MD Anderson))&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=13985dd6a939e0e4f8998620b4a428b1&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: hWFURkY5)&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;2. CID Program Update&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;A Bayesian Adaptive Trial in Duchenne Muscular Dystrophy (Steve Lake (Wave Life Sciences))&lt;/li&gt;
&lt;li&gt;Innovative Designs in the Rare Disease Setting (Dionne Price (FDA))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=1bc6e1d02b1002d62c170a17473e3d54&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: pMbpsJT7)&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;3. Gene Therapy in Rare Disease Development&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Gene Therapy: Opportunities and Challenges for the Treatment of Hemophilia (Michelle Casey (Pfizer))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=ccaaeefdd89e63e72892e9650397f117&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: NERDS456)&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;4. Case Studies in Rare Disease Drug Development&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Lessons from Notable New Drug Application involving External Controls (Margaret (Meg) Gamalo (Pfizer))&lt;/li&gt;
&lt;li&gt;Design and Analysis of Drop the Losers Studies in the Rare Disease Setting (Glen Laird (Vertex))&lt;/li&gt;
&lt;li&gt;A Case Study Using Nature History Data to Understand Long Term Disease Progression (Cindy Lu (Biogen))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=e227bbfd8699459593dffc5ce07cd795&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: Pq8pBWgU)&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Innovations in Bayesian Clinical Trials Interactive Workshops</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015innovations-in-bayesian-clinical-trials-interactive-workshops/</link>
      <pubDate>Thu, 15 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015innovations-in-bayesian-clinical-trials-interactive-workshops/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 1: Essentials of Bayesian Statistics&lt;/strong&gt;&lt;br&gt;
October 15, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691551&amp;amp;sessionid=1&amp;amp;key=109B6B88F22396785524BCAD42C50522&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 2: Bayesian Meta-Analysis and Hierarchical Models&lt;/strong&gt;&lt;br&gt;
October 29, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691558&amp;amp;sessionid=1&amp;amp;key=8543F409BD3894D06579F92276808A5D&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 3: Prior Distributions (Part I)&lt;/strong&gt;&lt;br&gt;
November 12, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691561&amp;amp;sessionid=1&amp;amp;key=238DEB3AC5D91E14B89095AF22C63D05&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>12th Annual Sentinel Initiative Public Workshop</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/2020101412th-annual-sentinel-initiative-public-workshop/</link>
      <pubDate>Wed, 14 Oct 2020 10:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/2020101412th-annual-sentinel-initiative-public-workshop/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session I: A Robust Sentinel System for the 21st Century&lt;/strong&gt;&lt;br&gt;
Objective: In response to new legislative mandates and the desire to diversify scientific expertise and enhance core key capabilities in the Sentinel System, the Center for Drug Evaluation and Research (CDER) has awarded a new five-year contract that establishes a new organizational structure for the Sentinel Coordinating Center. This new contract builds on FDA successes integrating the active, post-market safety surveillance into regulatory decision-making. This session will feature key leads from each Sentinel coordinating center who will discuss plans on how to advance and transform Sentinel’s data infrastructure into a national resource for evidence generation. Panelists will also discuss opportunities for collaboration to broaden stakeholder involvement, improve access to new data sources and analytic tools, and ensure more efficient and effective safety surveillance activities.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session II: Building the BEST Network and Establishing New Capabilities for the Surveillance of Biologics&lt;/strong&gt;&lt;br&gt;
Objective: Launched in 2017, the BEST Initiative enacts the Agency’s mandate to implement active surveillance for biologic products. This session will highlight key achievements of BEST over the last year enhancing its capabilities to execute safety and effectiveness surveillance and inform regulatory decision making. CBER representatives will discuss ongoing work to support the expansion of the BEST data network and methods infrastructure as well as specific studies utilizing the infrastructure.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session III: Leveraging the Sentinel Initiative for COVID-19&lt;/strong&gt;&lt;br&gt;
Objective: The U.S. FDA’s Sentinel Initiative is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic. This session will highlight key ongoing efforts across CDER and CBER to leverage Sentinel data infrastructure to describe course of illness, and evaluate the utilization, safety, and effectiveness of available COVID-19 therapeutics and vaccines under real-world conditions.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Cytel’s New Horizons Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</link>
      <pubDate>Mon, 05 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Increasing the Power of Platform Trials: Efficient Multi-Arm Multi-Stage Adaptive Designs&lt;/strong&gt;&lt;br&gt;
Speaker: Cyrus Mehta&lt;br&gt;
October 5, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2713671&amp;amp;sessionid=1&amp;amp;key=DEC35F5F99E3B346CD3428FB63E00EA1&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;The Value of Detailed Statistical Trial Simulations – A Case Study for Rare Diseases&lt;/strong&gt;&lt;br&gt;
Speaker: Ursula Garczarek&lt;br&gt;
October 26, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2754403&amp;amp;sessionid=1&amp;amp;key=5190486304A26AF8A168A9EB5762E412&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Key Design Considerations for Adaptive Platform Trials&lt;/strong&gt;&lt;br&gt;
Speaker: Jay Park&lt;br&gt;
November 2, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803072&amp;amp;sessionid=1&amp;amp;key=B00AA58DD8F16FD72214ED83EAE3F56C&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;AI in Clinical Research: Prediction and Causal Inference&lt;/strong&gt;&lt;br&gt;
Speaker: Alind Gupta&lt;br&gt;
November 9, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803079&amp;amp;sessionid=1&amp;amp;key=F30F710608E4E55C3E02D0193E42FEAB&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>COVID-19: Pandemic Preparedness and Lessons Learned</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</link>
      <pubDate>Wed, 10 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;An overview of how COVID-19 progressed&lt;/li&gt;
&lt;li&gt;How can pharmaceutical companies be better prepared? Should there be plans and clinical development strategies in place?&lt;/li&gt;
&lt;li&gt;How do we build resiliency? What steps could/should be implemented at various stages to ‘flatten the curve’?&lt;/li&gt;
&lt;li&gt;Vulnerable communities and minority populations are at a disadvantage. How do we address these health disparities?&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
  </channel>
</rss>
